Cardiology 2013

 

 

Reference Type:  Journal Article

Record Number: 784Author: Hausenloy, D. J., Erik Botker, H., Condorelli, G., Ferdinandy, P., Garcia-Dorado, D., Heusch, G., Lecour, S., van Laake, L. W., Madonna, R., Ruiz-Meana, M., Schulz, R., Sluijter, J. P., Yellon, D. M. and Ovize, M.

Year: 2013

Title: Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology

Journal: Cardiovasc Res

Volume: 98

Issue: 1

Pages: 7-27

Date: Apr 1

Short Title: Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology

Alternate Journal: Cardiovascular research

ISSN: 1755-3245 (Electronic)

0008-6363 (Linking)

DOI: 10.1093/cvr/cvt004

Accession Number: 23334258

Keywords: Animals

Cardiopulmonary Bypass

Cardiopulmonary Resuscitation

Collateral Circulation

Coronary Artery Bypass

Coronary Circulation

Coronary Disease/complications/*therapy

Disease Models, Animal

Heart Transplantation

Humans

Myocardial Reperfusion Injury/*prevention & control

Signal Transduction

Abstract: Coronary heart disease (CHD) is the leading cause of death and disability worldwide. Despite current therapy, the morbidity and mortality for patients with CHD remains significant. The most important manifestations of CHD arise from acute myocardial ischaemia-reperfusion injury (IRI) in terms of cardiomyocyte death and its long-term consequences. As such, new therapeutic interventions are required to protect the heart against the detrimental effects of acute IRI and improve clinical outcomes. Although a large number of cardioprotective therapies discovered in pre-clinical studies have been investigated in CHD patients, few have been translated into the clinical setting, and a significant number of these have failed to show any benefit in terms of reduced myocardial infarction and improved clinical outcomes. Because of this, there is currently no effective therapy for protecting the heart against the detrimental effects of acute IRI in patients with CHD. One major factor for this lack of success in translating cardioprotective therapies into the clinical setting can be attributed to problems with the clinical study design. Many of these clinical studies have not taken into consideration the important data provided from previously published pre-clinical and clinical studies. The overall aim of this ESC Working Group Cellular Biology of the Heart Position Paper is to provide recommendations for optimizing the design of clinical cardioprotection studies, which should hopefully result in new and effective therapeutic interventions for the future benefit of CHD patients.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208